Africa News Ledger
SEE OTHER BRANDS

The most trusted news from Africa

Africa News Ledger: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa News Ledger.

Press releases published on May 12, 2025

Interim Financial Results

Interim Financial Results

PERTH, Australia, May 12, 2025 (GLOBE NEWSWIRE) -- Paladin Energy Ltd (ASX:PDN, TSX:PDN, OTCQX:PALAF) (“Paladin” or the “Company”) advises that it has released its unaudited condensed interim financial report and management discussion and analysis (MD…

Elevate Consulting LLC Launches Results-Driven Mastermind to Advance Mid-Career Women in a Competitive Job Market

Elevate Consulting LLC Launches Results-Driven Mastermind to Advance Mid-Career Women in a Competitive Job Market

BRAINTREE, MA, UNITED STATES, May 12, 2025 /⁨EINPresswire.com⁩/ -- Backed by Coach Annie’s 20+ years of HR expertise, Elevate Me empowers professional women to unlock career clarity, confidence, and compensation In response to mounting challenges facing …

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context …

Cellectis Reports Financial Results for the First Quarter 2025

Cellectis Reports Financial Results for the First Quarter 2025

Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025 Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025 …

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

FDA Breakthrough Device Designation Awarded to AVIM Therapy FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch NEW HOPE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a …

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments Raised gross proceeds of ~$20 million in follow-on capital raise …

Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference

Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference

SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities 2025 …

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for AVMAPKI™FAKZYNJA™ CO-PACK

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for AVMAPKI™FAKZYNJA™ CO-PACK

LOUISVILLE, Ky., May 12, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Verastem Oncology for AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets …

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 152, …

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first …

Assertio Reports First Quarter 2025 Financial Results

Assertio Reports First Quarter 2025 Financial Results

First Quarter Total Net Product Sales of $26.0 Million, In Line with 2025 Outlook Provides Update on Long-Term Business Strategy Designed to Create Sustainable Near-Term Growth and Increased Long-Term Value LAKE FOREST, Ill., May 12, 2025 (GLOBE NEWSWIRE) …

Evolving Systems Highlights Evolution Marketplace as a Scalable Revenue Driver for Telecom Operators

Evolving Systems Highlights Evolution Marketplace as a Scalable Revenue Driver for Telecom Operators

Telecom operators turn to Evolution Marketplace to unlock new revenue, enable merchant ecosystems, and deliver personalized subscriber experiences. MANCHESTER, UNITED KINGDOM, May 12, 2025 /⁨EINPresswire.com⁩/ -- As revenue from traditional telecom …

Unlocking the Soaring Bitcoin Income, HashFly Launches a New Cloud Mining Plan for 2025 to Help Cryptocurrency Enthusiasts Maximize Passive Income

Unlocking the Soaring Bitcoin Income, HashFly Launches a New Cloud Mining Plan for 2025 to Help Cryptocurrency Enthusiasts Maximize Passive Income

London, UK, May 12, 2025 (GLOBE NEWSWIRE) -- As Bitcoin soars past $120,000 in 2025, driven by $10B in Q1 ETF inflows (CoinDesk), HashFly—a UK-founded cloud mining pioneer since 2013—unveils its boldest HashFly cloud mining plan to unlock this income for …

ALPHAMIN PROVIDES OPERATIONAL RESTART UPDATE

ALPHAMIN PROVIDES OPERATIONAL RESTART UPDATE

GRAND BAIE, MAURITIUS, May 12, 2025 (GLOBE NEWSWIRE) -- Alphamin Resources Corp. (AFM:TSXV, APH:JSE AltX) (the “Company”) is pleased to provide an update following the resumption of tin concentrate production on 15 April 2025. The Company’s Bisie tin mine …

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

May 12, 2025 Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted in 2019 Company nears start of Registrational Phase 3 …

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision

SARASOTA, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced it will host a management update webinar on …

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

LEIDEN, Netherlands …

Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement

Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement

Company Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today addresses frequently asked stockholder …

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders …

ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2025

ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2025

Successful completion of €30 Million capital increase, with strong international demand and oversubscription Awarded non-refundable EU grant of €13.26 Million through the first Important Project of Common European Interest (IPCEI) in the health sector ( …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service